Anaconda Pharma

Scientific breakthrough in HPV treatment

Anaconda Pharma

Scientific breakthrough in HPV treatment

Anaconda Pharma founded in 2003, was a spin-off from the Institut Pasteur focusing on the development of treatments against infections by Human Papillomavirus (HPV). Anaconda’s scientific co-founders are affiliated with the Institut Pasteur (Paris, France) and UC Berkeley (USA) and include some of the leading scientists in the field of HPV and related diseases.

 

Anaconda Pharma has successfully completed Phase IIa trial of its novel,  first in class therapeutic AP611074 against condyloma (ano-genital warts).

News

08.01.2014
from the scientific community for Anaconda Pharma.
19.12.2013
Anaconda s'attaque à une MST fréquente.
31.10.2013
Anaconda Pharma today announced the positive outcome of the Phase IIa trial of its novel, first-in-class therapeutic AP611074 against condyloma (ano-genital warts).